Praxis Precision Medicines (PRAX) Net Equity Issued and Repurchased (2019 - 2026)

Praxis Precision Medicines' Net Equity Issued and Repurchased history runs 7 years deep, the most recent figure standing at $621.2 million for Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $621.2 million in Q1 2026; TTM through Mar 2026 was $621.2 million, a 1379.6% increase from a year earlier, with the FY2024 full-year figure at $113.1 million, up 78.28% from the prior year.
• Net Equity Issued and Repurchased improved to $621.2 million in Q1 2026 per PRAX's latest filing, from $98.3 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $621.2 million in Q1 2026 and bottomed at -$146.9 million in Q2 2024.
• The 4-year median for Net Equity Issued and Repurchased is $18.1 million (2023), against an average of $88.6 million.
• Across the five-year window, Net Equity Issued and Repurchased jumped 1222.81% in 2023 and plunged 2535.08% in 2024, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at -$1.4 million in 2022, then soared by 2973.61% to $39.3 million in 2023, then soared by 150.15% to $98.3 million in 2024, then soared by 531.75% to $621.2 million in 2026.
• Per Business Quant, the three latest PRAX Net Equity Issued and Repurchased figures stand at $621.2 million (Q1 2026), $98.3 million (Q4 2024), and -$146.9 million (Q2 2024).